Research programme: cardiovascular therapeutics - Bio3 Research
Alternative Names: CT 301/R; CT 406; Mimic-Abs HMGB1-specific; siRNA HMGB1 specificLatest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Bio3 Research
- Class Monoclonal antibodies
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Italy (Parenteral)
- 19 Jul 2010 Preclinical development is ongoing in Italy
- 12 Feb 2007 Preclinical trials in Cardiovascular disorders in Italy (unspecified route)